- Home
- OGS vs RYTM Comparison
OGS vs RYTM Comparison
Compare OGS & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OGS | RYTM |
|---|---|---|
| Founded | 1906 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.4B |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | OGS | RYTM |
|---|---|---|
| Price | $84.97 | $75.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $85.25 | ★ $131.14 |
| AVG Volume (30 Days) | 400.8K | ★ 914.5K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.17% | N/A |
| EPS Growth | 11.76 | ★ 28.34 |
| EPS | ★ 4.37 | N/A |
| Revenue | ★ $2,578,005,000.00 | N/A |
| Revenue This Year | $11.97 | $55.17 |
| Revenue Next Year | N/A | $95.98 |
| P/E Ratio | $19.63 | ★ N/A |
| Revenue Growth | ★ 42.54 | N/A |
| 52 Week Low | $69.75 | $45.91 |
| 52 Week High | $88.03 | $122.20 |
Technical Indicators
Market Signals| Indicator | OGS | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 49.03 | 31.50 |
| Support Level | $83.77 | $60.71 |
| Resistance Level | $87.96 | $98.37 |
| Average True Range (ATR) | 1.34 | 5.71 |
| MACD | -0.35 | -0.74 |
| Stochastic Oscillator | 34.27 | 0.08 |
Price Performance
Historical ComparisonAbout OGS ONE Gas Inc.
ONE Gas Inc is a regulated natural gas utility company. It is involved in the distribution and sale of natural gas to residential, commercial, industrial, and transportation consumers through its network of pipelines and service lines. Almost all of the company's revenue is derived from natural gas sales in the states of Oklahoma, Kansas, and Texas. It operates in one reportable business segment: regulated public utilities that deliver natural gas to residential, commercial, and transportation customers.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.